In particular, the SGLT2 inhibitor empagliflozin has been reported to alleviate T2DM-related DKD by reducing LPS-producing bacteria and increasing SCFA-producing bacteria in DKD mice (Deng et al. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.